相关实验视频
Updated: Jun 24, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
重新审视结构-活性关系:释放选择性简氏激酶1抑制剂的潜力
Mengyi Shan1, Xuan Zhao1, Peng Sun1
1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, People's Republic of China.
Bioorganic chemistry
|June 4, 2024
概括
本综述强调了用于治疗炎症疾病的Janus激酶1 (JAK1) 抑制剂. 它检查了强大的JAK1化合物的结构-活性关系和药用性,提供了克服临床应用挑战的策略.
科学领域:
- 药用化学 医学化学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 简氏激酶 (JAKs) 是非受体氨酸激酶,对细胞信号传递,免疫反应和疾病的发病至关重要.
- JAK1是调节炎症和免疫功能的关键标,已批准的药物用于类风湿性关节炎和亚托邦性皮肤炎等疾病.
研究的目的:
- 审查目前市场和临床试验中的JAK1抑制剂.
- 分析高强度JAK1化合物 (IC50 ≤0.1nM) 的结构-活性关系 (SAR) 和选择性.
- 讨论已批准的JAK1药物和强效化合物的可用性,以及临床应用的挑战和解决方案.
主要方法:
- 在临床试验中批准的JAK1抑制剂和化合物的文献综述.
- 对高活性JAK1抑制剂的结构数据的分析.
- 评估SAR,选择性和药物适应性概况.
主要成果:
- 高活性JAK1抑制剂的鉴定和结构分析.
- 详细检查SAR和强效化合物的选择性.
- 评估与JAK1抑制剂相关的可药性和临床挑战.
结论:
- JAK1抑制剂代表了炎症和免疫媒介疾病的重要治疗策略.
- 了解SAR和可药性对于开发有效和安全的JAK1向疗法至关重要.
- 解决临床应用挑战将进一步优化JAK1抑制剂在患者护理中的使用.
相关概念视频
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.9K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

